To assess whether HSA normalization of AFB1-lys adduct levels corrects for diminished protein synthesis or metabolic function in individuals with hepatobiliary disease, as has been proposed, we replicated our analysis using data from two published case-control studies, both of which reported a significantly increased risk of gallbladder cancer with elevated AFB1 exposure [11,12]. This evidence concerns the gene ALB and gallbladder cancer.